MoonLake Immunotherapeutics (MLTX) Income from Continuing Operations (2021 - 2026)

MoonLake Immunotherapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 69707000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 71.87% year-over-year to 69707000.0; the TTM figure through Mar 2026 stood at 259470000.0 (down 75.52% YoY), while the FY2025 annual figure was 230321000.0, down 89.96% from the prior year.
• Income from Continuing Operations was 69707000.0 for Q1 2026 at MoonLake Immunotherapeutics, down from 63018000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 7887273.0 in Q4 2023 to a low of 70694000.0 in Q3 2025.
• Historically, Income from Continuing Operations has averaged 31168061.71 across 5 years, with a median of 17416329.0 in 2022.
• Biggest YoY gain for Income from Continuing Operations was 69.3% in 2022; the steepest drop was 20715.22% in 2022.
• A 5-year view of Income from Continuing Operations shows it stood at 16467930.0 in 2022, then jumped by 52.11% to 7887273.0 in 2023, then sank by 488.23% to 46395000.0 in 2024, then slumped by 35.83% to 63018000.0 in 2025, then retreated by 10.61% to 69707000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 69707000.0 (Q1 2026), 63018000.0 (Q4 2025), and 70694000.0 (Q3 2025), per Business Quant data.